Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390945 | 0.88 | GPR119 (0.69) | GPR119CYP2C9KCNH2TP53ALDH1A1 | |
| SCHEMBL390373 | 0.80 | GPR119 (0.66) | GPR119CYP2C9KCNH2TP53ALDH1A1 | |
| SCHEMBL13404755 | 0.78 | GPR119 (0.68) | GPR119CYP2C9KCNH2TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL1244802 | 0.76 | GPR119 (0.70) | GPR119CYP2C9KCNH2TP53ALDH1A1 | |
| SCHEMBL388933 | 0.75 | GPR119 (0.82) | GPR119CYP2C9KCNH2CYP3A4 | |
| SCHEMBL27866120 | 0.75 | GPR119 (0.73) | GPR119CYP2C9KCNH2TP53ALDH1A1 | |
| SCHEMBL386157 | 0.72 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL6402961 | 0.71 | GPR119 (0.77) | GPR119CYP2C9KCNH2CYP3A4 | |
| SCHEMBL389811 | 0.70 | GPR119 (0.72) | GPR119CYP2C9KCNH2CYP3A4 | |
| SCHEMBL5652796 | 0.70 | GPR119 (0.51) | GPR119TP53ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICLAS, INC. (US) | 2007-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | GPR119 36/4885CYP2C9 55/4885KCNH2 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.